A Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2016
At a glance
- Drugs TAS 115 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 12 Aug 2016 Planned number of patients changed from 67 to 90.
- 12 Aug 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2018.
- 02 Jun 2015 Interim results in 18 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).